Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Carboplatin, Paclitaxel, Bevacizumab; Drug
Lead sponsor: Jason D. Wright; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania • Charlottesville, Virginia

Conditions: Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions: 177Lu-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer Weight Loss
Interventions: TCMCB07, Placebo; Drug
Lead sponsor: Endevica Bio; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Diabetes Mellitus, Type 1
Interventions: ACCU-CHEK; Device
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Montgomery, Alabama • Huntington Beach, California • Atlanta, Georgia + 8 more

Conditions: Turner Syndrome, Idiopathic Short Stature
Interventions: somatropin (rDNA); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 14 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 18 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Diabetic Retinopathy
Interventions: I-SITE; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: PreDiabetes
Interventions: Registered Dietitian/Nutritionist, Diabetes Prevention Program, Weight Watchers, Reimagined, DPP or RDN Counseling + Medication, Bariatric Surgery Evaluation; Behavioral · Other
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Oxidative Stress, Healthy Aging, Skin Health
Interventions: Solarplast; Dietary Supplement
Lead sponsor: Deerland Enzymes; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Interventions: PF-08046049; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 27
States / cities: Los Angeles, California • Pasadena, California • San Francisco, California + 11 more

Conditions: Diabetes, Diabetes Type 2
Interventions: Integrated Digital Health (IDH) platform, Provider engagement; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions: Self blood glucose monitoring and insulin administration, Standard care; Procedure
Lead sponsor: Atlanta VA Medical Center; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Primary Aldosteronism
Interventions: Adrenalectomy, mineralocorticoid receptor antagonist; Other · Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: bubble packaging for monthly prescription; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Ovarian Neoplasms, Peritoneal Neoplasms
Interventions: Placebo, Paclitaxel, BIBF 1120, Carboplatin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 33
States / cities: Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more

Conditions: WAGR Syndrome, Wilm's Tumor, Aniridia, Urogenital Abnormalities, Mental Retardation
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 99 Years
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Blinded CGM, real-time CGM; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CareSens Air 3 primary insertion, CareSens Air 3 secondary insertion; Device
Lead sponsor: i-SENS, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more

Conditions: Diabetes Mellitus, Adult Onset
Interventions: Cinnamon or placebo 500 mg capsule twice daily; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreatic Cancer
Interventions: Talabostat Mesylate; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Obesity, Type 2 Diabetes
Interventions: HEALTH[e]TEEN, HEALTH[e]TEEN + CST; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Melanoma
Interventions: Schirmer strip, a Class I Medical Device typically used to test for dry eye.; Other
Lead sponsor: Namida Lab; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 13
States / cities: Northridge, California • Port Hueneme, California • Waterbury, Connecticut + 9 more

Search by objective public record fields.

Neoadjuvant Therapy for Ovarian Cancer

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

Designing Team Clinic for Youth With Type 2 Diabetes

I-TRUST: Implementation of Teleophthalmology in Rural Health Systems Study

Preventing Diabetes

Efficacy of Solarplast for Health and Oxidative Stress

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Glucose, Understanding, Integrated Digital Health, and Engagement (GUIDE) Study

Inpatient Self Monitoring and Administration Study (ISMAS)

Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions

Time in Glucose Hospital Target

Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Reducing Obesity and Type 2 Diabetes in High Risk Youth

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants